Image

Global Monkeypox Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Aug 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Aug 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Monkeypox Market, By Treatment (Cidofovir, Brincidofovir, Tecovirimat, Vaccinia ImmuneGlobulin), End-Users (Clinics, Hospitals, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Monkeypox Market

Monkeypox Market Analysis and Size

The monkeypox market is expected to witness significant growth during the forecast period. Rise in risk of zoonotic disease transmission and the growing preference for biological therapies boosted the market growth. In addition, increasing research and development and improved government support also boost market growth. In addition to this, treatment advances and the establishment of well-defined healthcare facilities are some of the major factors for the demand of global monkeypox market. COVID-19 also left a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the monkeypox market in the forecast period 2022-2029. The expected CAGR of global monkeypox market is tend to be around 5.40% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Monkeypox is a type of zoonotic disease that is caused due to transmission of virus from animals to humans. The symptoms correlate quite well with that of small pox. The people of Central and West Africa are more prone to monkeypox. Monkey pox has been witnessed to get transmitted via pet prairie dogs which have been infected with African rodents. The cases of monkeypox have also been reported in Israel, U.K., Nigeria, and others. The specific treatment for monkeypox is not yet available but it can be controlled and prevented by vaccines used for small pox.  

Monkeypox Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Treatment (Cidofovir, Brincidofovir, Tecovirimat, Vaccinia Immune Globulin), End-Users (Clinics, Hospitals, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Bavarian Nordic (Denmark), SIGA Technologies (U.S.), Chimerix (U.S.), BioFactura, Inc. (U.S.), Tonix Pharmaceuticals Holding Corp. (U.S.), SymBio Pharmaceuticals Limited (Japan), Gilead Sciences, Inc. (U.S.), Aspen Holdings (South Africa), Emcure Pharmaceuticals (India), Baxter (U.S.), Grifols S.A. (Spain), EMERGENT (U.S.), Hetero (India), Olon S.p.A. (Italy), Piramal Enterprises Ltd. (India)

Market Opportunities

  • Increased Research Development and Activities
  • Increasing Demand for Retail Pharmacies

Global Monkeypox Market Dynamics

Drivers

  • Rising Prevalence of Monkeypox

The cases of monkeypox are on the rise with each passing day. As per the reports of WHO, since 13 May 2022, and as of 2 June 2022, almost 780 confirmed cases of monkeypox have been witnessed or identified from around 27 Member States. After the outbreak of the disease in 29 May, an increase of 523 laboratory confirmed cases were witnessed. Thus, it boosts the market growth.

  • Rise in Investors For Monkeypox Vaccines and Drugs

There are multiple shares of antiviral drug makers, vaccine producers, and protective equipment manufacturers are in demand as investors are playing on a strategy that proved to be quite advantageous during the coronavirus pandemic. As of now, biotechnological company Bavarian Nordic A/S and pharmaceutical firm Siga Technologies Inc. are among the rising stocks that are in focus along with the medical tools supplier Precision System Science Co. All these factors are boosting the market growth.

Opportunities

  • Increasing Demand for Retail Pharmacies

Rise in the number of discovery of therapeutics of monkeypox being delivered through retail pharmacies and rise in retail pharmacies in developed countries create new opportunities for the growth of the global monkeypox market. Additionally, patients preferably choose retail pharmacies for purchasing drugs, due to its easy accessible nature.

  • Increased Research and Development Activities

The increasing investment in R&D activities, increasing government support for the vaccination programs, and rising awareness boost growth opportunities to the market. For instance, there are two vaccines that are developed which may be used for the prevention of monkeypox disease. One such is JYNNEOS vaccine which is approved for the prevention of monkeypox and smallpox disease. Another one is ACAM2000 vaccine which is approved for immunization against smallpox disease and was made accessible to treat patients with monkeypox under an Expanded Access Investigational New Drug (EA-IND) protocol. This boost the market growth.

 Restraints/Challenges

  • Lack of skilled professionals

The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global monkeypox market over a forecast period.

  • High Cost

The huge expenditure associated with monkeypox treatment medications and vaccines surely hamper the market growth.

This global monkeypox market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global monkeypox market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Impact of COVID-19 on Global Monkeypox Market

The world was slightly residing apart from the severe impact of the coronavirus pandemic, the World Health Organization (WHO) has now alarmed the general population over a new viral disease, monkeypox, which is spreading rapidly and creating havoc around the world. The global monekypox market is independent from the severity of covid-19 pandemic as in the post pandemic era, the market is slightly uplifted from the vaccine production and therapeutics for covid-19. And now as the monkeypox virus is expanding, the market is facing a huge growth due to the production of vaccines and drugs for the same.

Global Monkeypox Market Scope

The global monkeypox market is segmented on the basis of treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

  • Cidofovir
  • Brincidofovir
  • Tecovirimat
  • Vaccinia Immune Globulin

End-Users

  • Clinics
  • Hospitals
  • Others

Distribution Channel

  • Direct Tender
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Monkeypox Market Regional Analysis/Insights

The global monkeypox market is analysed and market size insights and trends are provided by treatment, distribution channel and end-user as referenced above.

The major countries covered in the global monkeypox market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for monkeypox market throughout the forecast period due to the presence of rising healthcare expenditure and favorable reimbursement policies for immunoglobulin.

Middle-East & Africa is dominating the market over coming years for the monkeypox market as the disease is highly prevalent in African countries and region nearby tropical rainforest, among others.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Monkeypox Market Share Analysis

The monkeypox market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to monkeypox market.

Key players operating in the monkeypox market include:

  • Bavarian Nordic (Denmark)
  • SIGA Technologies (U.S.)
  • Chimerix (U.S.)
  • BioFactura, Inc. (U.S.)
  • Tonix Pharmaceuticals Holding Corp. (U.S.)
  • SymBio Pharmaceuticals Limited (Japan)
  • Gilead Sciences, Inc. (U.S.)
  • Aspen Holdings (South Africa)
  • Emcure Pharmaceuticals (India)
  • Baxter (U.S.)
  • Grifols S.A. (Spain)
  • EMERGENT (U.S.)
  • Hetero (India)
  • Olon S.p.A. (Italy)
  • Piramal Enterprises Ltd. (India)


SKU-
Why Choose Us


Frequently Asked Questions

The global monkeypox market is projected to grow at a CAGR of 5.40% during the forecast period of 2022-2029.
The significant factors flourishing the growth of the Monkeypox Market are Rising Prevalence of Monkeypox, and Rise in Investors For Monkeypox Vaccines and Drugs.
The major players operating in the Monkeypox Market are Bavarian Nordic (Denmark), SIGA Technologies (U.S.), Chimerix (U.S.), BioFactura, Inc. (U.S.), Tonix Pharmaceuticals Holding Corp. (U.S.), SymBio Pharmaceuticals Limited (Japan), Gilead Sciences, Inc. (U.S.), Aspen Holdings (South Africa), Emcure Pharmaceuticals (India), Baxter (U.S.), Grifols S.A. (Spain), EMERGENT (U.S.), Hetero (India), Olon S.p.A. (Italy), Piramal Enterprises Ltd. (India).
The major countries covered in the Monkeypox Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.